Mayzent and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Mayzent (siponimod fumaric acid), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Mayzent. It is created by eHealthMe based on reports of 10,267 people who have side effects when taking Mayzent from the FDA, and is updated regularly.

What is Mayzent?

Mayzent has active ingredients of siponimod fumaric acid. eHealthMe is studying from 10,269 Mayzent users. Check the latest studies of Mayzent.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,592 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 23, 2026

10,267 people reported to have side effects when taking Mayzent.
Among them, 17 people (0.17%) have Agranulocytosis.

Among these 17 people:

How long have people been on Mayzent when they have Agranulocytosis? *

What is the gender of people who have Agranulocytosis when taking Mayzent? *

female: 75 %
male: 25 %

What is the age of people who have Agranulocytosis when taking Mayzent? *

What are other drugs people take besides Mayzent? *

Pregabalin: 2 people, 11.76%
Ibuprofen: 2 people, 11.76%
Gilenya: 2 people, 11.76%
Vitamin D2: 1 person, 5.88%
Valacyclovir Hydrochloride: 1 person, 5.88%
Topamax: 1 person, 5.88%
Potassium: 1 person, 5.88%
Paxil: 1 person, 5.88%
Mobic: 1 person, 5.88%
Mesalamine: 1 person, 5.88%

What are other side effects people have besides Agranulocytosis? *

Lymphocyte Count Decreased: 6 people, 35.29%
White Blood Cell Count Decreased: 5 people, 29.41%
Lymphopenia (an abnormally low level of lymphocytes in the blood): 4 people, 23.53%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 3 people, 17.65%
Dyspnea (difficult or laboured breathing): 3 people, 17.65%
Mean Cell Volume Decreased (less of the average red blood cell volume): 2 people, 11.76%
Low Density Lipoprotein Increased (cholesterol increased in blood): 2 people, 11.76%
High Blood Cholesterol: 2 people, 11.76%
Osteoporosis (bones weak and more likely to break): 2 people, 11.76%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 11.76%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 9 people, 52.94%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 7 people, 41.18%
Urge Incontinence (urinary incontinence): 1 person, 5.88%
Neuralgia (pain in one or more nerves): 1 person, 5.88%
Muscle Rigidity (muscle stiffness): 1 person, 5.88%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
Movement - Uncoordinated: 1 person, 5.88%
Depression: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Mayzent and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mayzent:

Mayzent (10,269 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Mayzent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,592 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on siponimod fumaric acid (the active ingredients of Mayzent) and Mayzent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.